

Solve-RD Publication Policy

Version	V2.1
Date	18 December 2020 (V2.1) 18 April 2018 (V2)
History of changes	V2.1: Update Annex I (Solve-RD author list)
Authors	Holm Graessner, Tina Harmuth
Approved by SC	24.4.2018 (V2)

1 Solve-RD as an author (if allowed for by journal)

An affiliation list will be created and regularly updated and will contain all members of the Solve-RD consortium (see Annex I). This list will determine the Solve-RD author ('Solve-RD consortium'). The author list will be reviewed and updated with each publication submission that makes use of the author list by the project management team (lead: Holm Graessner). The Solve-RD author shall be used for all publications if allowed for by the journal.

2 Notification and authorship policy with regard to shared data

All Solve-RD publications are acknowledged to be based on the fundamental principles of open scientific collaboration, reciprocity, attribution and benefit sharing. For any publication resulting from work carried out using data shared or generated through Solve-RD (e.g. for identifying a novel gene), including where data has been accessed through the RD-Connect Genome-Phenome Analysis Platform, the authors should in all cases acknowledge and give appropriate authorship positions to all relevant parties in line with best practice for acknowledgement of scientific contribution including submission of the primary data.

Examples and further principles are described below.

- 1. A publication arising from research in which the party leading the publication ("the PI team") is primarily analysing their own submitted data (example: novel gene discovery by a submitter analysing their own patient cohorts in the RD-Connect GPAP):**
 - i. Where a publication only includes data and hypotheses from the PI's own research group, key authorship positions may be held by this group, but the software, tools and resources made use of for the research should be duly acknowledged and referenced in line with the policies for those resources (e.g. see RD-Connect GPAP policy below). Where justified, individuals supporting the bioinformatics analysis or platforms may be approached for co-authorship based on individual scientific contribution.
 - ii. Where a publication has involved the use or analysis of data from additional submitters, these submitters should be contacted as soon as possible ahead of publication and invited to provide input as co-authors. The PI team is strongly encouraged to share key authorship positions with other teams that have brought in similar intellectual input and/or fundamental data (e.g. "a second family"). Acknowledgement of bioinformatics support should also be considered as in (a) above.
- 2. A publication arising from the analysis of data where the party generating the hypothesis and carrying out the analysis is not themselves the data submitter (example: reanalysis of data by a Solve-RD bioinformatics group that did not submit the data or see the patients):**
 - i. Submitters of the data used for the analysis should be contacted as soon as possible ahead of publication and invited to provide input as co-authors. The PI team is strongly encouraged to share key authorship positions with the submitting teams based on the value and amount of data contributed to the publication. If the primary data is the key to

discovery, a key authorship position should be discussed with the owner of the primary data.

- ii. Where a publication makes use of data from a large number of submitters or transversal analysis of the Solve-RD cohort, a group authorship for Solve-RD should be considered in order to acknowledge the role of all data submitters equally.

All data access through the RD-Connect genome-phenome analysis platform is monitored automatically by the system and all other data access for other Solve-RD activities is only to named individuals within the Solve-RD consortium, therefore any breach of the publication policy will be monitored and flagged up to the Solve-RD Steering Committee.

3 Confirmation of paper by Solve-RD Consortium

During the project and for a period of one (1) year after the project every paper that is published with affiliation of Solve-RD or includes data produced or collated within Solve-RD has to be confirmed by the Solve-RD Consortium. The procedure is defined in Article 29.1 of the Solve-RD Grant Agreement and Article 8.4.2 of the Solve-RD Consortium Agreement. All Parties and associated Partners (including associated ERNs) are obliged to follow this procedure.

Prior notice of any planned publication shall be given to the other Parties at least 45 calendar days before the intended date of publication. Any objection to the planned publication following the above notification shall be made in accordance with the Grant Agreement in writing to the Coordinator and to the Party or Parties proposing the dissemination within thirty (30) calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted.

An objection is justified if (a) the protection of the objecting Party's Results or Background would be adversely affected and/or (b) the objecting Party's legitimate academic or commercial interests in relation to the Results or Background would be significantly harmed.

The objection has to include a precise and reasonable request for necessary modifications, it being specified that any such modifications shall not harm the scientific content of the proposed publication or communication.

If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion. The objecting Party can request a publication delay of not more than 90 calendar days from date of submission to the other Parties. After 90 calendar days the publication is permitted provided that Confidential Information of the objecting Party has been removed from the Publication and all reasonable modifications of the objecting Party have been implemented within the Publication as indicated by the objecting Party.

A decision has to be made and communicated within four weeks after submission of the publication draft (author list and abstract) to the Steering Committee.

4 Parallel Analysis of submitted data at centres

The Steering Committee has to be informed if data sets that were submitted to Solve-RD for central analysis go through in house analysis that may lead to publications.

5 Acknowledgements

Solve-RD funding acknowledgement

Any publications arising from Solve-RD project funding should acknowledge it in the following way:

“This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD).”

RD-Connect GPAP acknowledgement

In addition to authorship positions as described above, any publications that arise from the use of the RD-Connect Genome Phenome Analysis Platform should acknowledge it in the following way:

“This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.”

In addition, the following paper should be cited:

Lochmüller H & Badowska D, Thompson R, Knoers N, Aartsma-Rus A, Gut I, Wood L, Harmuth T, Durudas A, Graessner H, Schaefer F & Rieß O. RD-Connect, NeurOmics and EURenOmics: Collaborative European Initiative for Rare Diseases. European Journal of Human Genetics. 2018.

ERN acknowledgement

Any publications with contributions from ERNs should acknowledge involved ERNs in the following way:

“This study was supported by the European Reference Network(s) [add ERN names] (https://ec.europa.eu/health/ern/networks_en).”

Annex I: Solve-RD author list

EKUT: Olaf Riess^{1,2}, Tobias B. Haack¹, Holm Graessner^{1,2}, Birte Zurek^{1,2}, Kornelia Ellwanger^{1,2}, Stephan Ossowski¹, German Demidov¹, Marc Sturm¹, Julia M. Schulze-Hentrich¹, Rebecca Schüle^{3,4}, Christoph Kessler^{3,4}, Melanie Wayand^{3,4}, Matthias Synofzik^{3,4}, Carlo Wilke^{3,4}, Andreas Traschütz^{3,4}, Ludger Schöls^{3,4}, Holger Hengel^{3,4}, Peter Heutink^{3,4}.

RUMC: Han Brunner^{5,6,7}, Hans Scheffer^{5,6}, Nicoline Hoogerbrugge^{5,8}, Alexander Hoischen^{5,8,9}, Peter A.C. 't Hoen^{8,10}, Lisenka E.L.M. Vissers^{5,7}, Christian Gilissen^{5,8}, Wouter Steyaert^{5,8}, Karolis Sablauskas⁵, Richarda M. de Voer^{5,8}, Erik-Jan Kamsteeg⁵, Bart van de Warrenburg^{7,11}, Nienke van Os^{7,11}, Iris te Paske^{5,8}, Erik Janssen^{5,8}, Elke de Boer^{5,7}, Marloes Steehouwer⁵, Burcu Yaldiz⁵, Tjitske Kleefstra^{5,7}.

University of Leicester: Anthony J. Brookes¹², Colin Veal¹², Spencer Gibson¹², Marc Wadsley¹², Mehdi Mehtarizadeh¹², Umar Riaz¹², Greg Warren¹², Farid Yavari Dizjikan¹², Thomas Shorter¹².

UNEW: Ana Töpf¹³, Volker Straub¹³, Chiara Marini Bettolo¹³, Sabine Specht¹³.

MUH: Jill Clayton-Smith¹⁴, Siddharth Banka^{14,15}, Elizabeth Alexander¹⁴, Adam Jackson¹⁴.

DIJON: Laurence Faivre^{16,17,18,19,20}, Christel Thauvin^{17,18,19,20}, Antonio Vitobello¹⁸, Anne-Sophie Denommé-Pichon¹⁸, Yannis Duffourd^{18,19}, Emilie Tisserant¹⁸, Ange-Line Bruel¹⁸, Christine Peyron^{21,22}, Aurore Pélissier^{22,22}.

CNAG-CRG: Sergi Beltran^{23,24}, Ivo Glynne Gut^{24,24}, Steven Laurie²⁴, Davide Piscia²⁴, Leslie Matalonga²⁴, Anastasios Papakonstantinou²⁴, Gemma Bullich²⁴, Alberto Corvo²⁴, Carles Garcia²⁴, Marcos Fernandez-Callejo²⁴, Carles Hernández²⁴, Daniel Picó²⁴, Ida Paramonov²⁴, Hanns Lochmüller²⁴.

EURORDIS: Gulcin Gumus²⁵, Virginie Bros-Facer²⁶.

INSERM-Orphanet: Ana Rath²⁷, Marc Hanauer²⁷, Annie Olry²⁷, David Lagorce²⁷, Svitlana Havrylenko²⁷, Katia Izem²⁷, Fanny Rigour²⁷.

INSERM-ICM: Giovanni Stevanin^{28,29,30,31,32}, Alexandra Durr^{29,30,31,31,33}, Claire-Sophie Davoine^{29,30,31,32,32}, Léna Guillot-Noel^{29,30,31,32,32}, Anna Heinzmann^{29,30,31,31,34}, Giulia Coarelli^{29,30,31,31,34}.

INSERM-CRM: Gisèle Bonne³⁵, Teresinha Evangelista³⁵, Valérie Allamand³⁵, Isabelle Nelson³⁵, Rabah Ben Yaou^{35,36,37}, Corinne Metay^{35,38}, Bruno Eymard^{35,36}, Enzo Cohen³⁵, Antonio Atalaia³⁵, Tanya Stojkovic^{35,36}.

Univerzita Karlova: Milan Macek Jr.³⁹, Marek Turnovec³⁹, Dana Thomasová³⁹, Radka Pourová Kremliková³⁹, Vera Franková³⁹, Markéta Havlovicová³⁹, Vlastimil Kremlik³⁹.

EMBL-EBI: Helen Parkinson⁴⁰, Thomas Keane⁴⁰, Dylan Spalding⁴⁰, Alexander Senf⁴⁰.

Jackson Laboratory: Peter Robinson⁴¹, Daniel Danis⁴¹.

KCL: Glenn Robert⁴², Alessia Costa^{42,42}, Christine Patch^{42,42,43}.

UCL-IoN: Mike Hanna⁴⁴, Henry Houlden⁴⁵, Mary Reilly⁴⁴, Jana Vandrovcova⁴⁵.

UCL-ICH: Francesco Muntoni^{46,47}, Irina Zaharieva⁴⁶, Anna Sarkozy⁴⁶.

Universiteit Antwerpen: Vincent Timmerman^{48,49}, Jonathan Baets^{50,51,52}, Liedewei Van de Vondel^{49,50}, Danique Beijer^{49,50}, Peter de Jonghe^{49,51}.

Uni Naples: Vincenzo Nigro^{53,54}, Sandro Banfi^{53,54}, Annalaura Torella⁵³, Francesco Musacchia^{53,54}, Giulio Piluso⁵³.

UNIFE: Alessandra Ferlini⁵⁵, Rita Selvatici⁵⁵, Rachele Rossi⁵⁵, Marcella Neri⁵⁵.

UKB: Stefan Aretz^{56,57}, Isabel Spier^{56,57}, Anna Katharina Sommer⁵⁶, Sophia Peters⁵⁶.

IPATIMUP: Carla Oliveira^{58,59,60}, Jose Garcia Pelaez^{58,59}, Ana Rita Matos^{58,59}, Celina São José^{58,59}, Marta Ferreira^{58,59}, Irene Gullo^{58,59,60}, Susana Fernandes^{58,61}, Luzia Garrido⁶², Pedro Ferreira^{58,59,63}, Fátima Carneiro^{58,59,60}.

UMCG: Morris A. Swertz⁶⁴, Lennart Johansson⁶⁴, Joeri K. van der Velde⁶⁴, Gerben van der Vries⁶⁴, Pieter B. Neerinx⁶⁴, Dieuwke Roelofs-Prins⁶⁴.

Charité: Sebastian Köhler⁶⁵.

SHU: Alison Metcalfe^{42,66}.

APHP: Alain Verloes^{67,68}, Séverine Drunat^{67,68}.

CHU Bordeaux: Caroline Rooryck⁶⁹, Aurelien Trimouille⁷⁰

Telethon UDP: Raffaele Castello⁵⁴, Manuela Morleo⁵⁴, Michele Pinelli⁵⁴, Alessandra Varavallo⁵⁴.

Spain UDP: Manuel Posada De la Paz⁷¹, Eva Bermejo Sánchez⁷¹, Estrella López Martín⁷¹, Beatriz Martínez Delgado⁷¹, F. Javier Alonso García de la Rosa⁷¹

Ospedale Pediatrico Bambino Gesù, Rome: Andrea Cioffi⁷², Bruno Dallapiccola⁷², Simone Pizzi⁷², Francesca Clementina Radio⁷², Marco Tartaglia⁷²

University of Siena: Alessandra Renieri^{73,74,75}, Elisa Benetti⁷³

Semelweis University Budapest: Peter Balicza⁷⁶, Maria Judit Molnar⁷⁶

University of Ljubljana: Ales Maver⁷⁷, Borut Peterlin⁷⁷

University of Lübeck: Alexander Münchau⁷⁸, Katja Lohmann⁷⁸, Rebecca Herzog⁷⁸, Martje Pauly⁷⁸

Val d'Hebron Barcelona: Alfons Macaya⁷⁹, Anna Marcé-Grau⁷⁹

Hospital Sant Joan de Déu Barcelona: Andres Nascimiento Osorio⁸⁰, Daniel Natera de Benito⁸⁰

University of Freiburg: Hanns Lochmüller^{81,82,83}, Rachel Thompson^{81,83}, Kiran Polavarapu⁸¹

University of Oxford: David Beeson⁸⁴, Judith Cossins⁸⁴, Pedro M. Rodriguez Cruz⁸⁴

University of Tampere: Peter Hackman⁸⁵, Mridul Johari⁸⁵, Marco Savarese⁸⁵, Bjarne Udd^{85,86,87}

University of Cambridge: Rita Horvath⁸⁸

Catalan Institute of Oncology, Barcelona: Gabriel Capella⁸⁹, Laura Valle⁸⁹

KU Munich: Elke Holinski-Feder⁹⁰, Andreas Laner⁹⁰, Verena Steinke-Lange⁹⁰

TU Dresden: Evelin Schröck⁹¹, Andreas Rump^{91,92}

¹ Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

² Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.

³ Department of Neurodegeneration, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.

⁴ German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

⁵ Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

⁶ Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁷ Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

⁸ Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.

⁹ Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.

¹⁰ Center for Molecular and Biomolecular Informatics, Radboud university medical center, Nijmegen, The Netherlands.

¹¹ Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.

¹² Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.

¹³ John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

- ¹⁴ Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK.
- ¹⁵ Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
- ¹⁶ Dijon University Hospital, Genetics Department, Dijon, France.
- ¹⁷ Dijon University Hospital, Centre of Reference for Rare Diseases: Development disorders and malformation syndromes, Dijon, France.
- ¹⁸ Inserm - University of Burgundy-Franche Comté, UMR1231 GAD, Dijon, France.
- ¹⁹ Dijon University Hospital, FHU-TRANSLAD, Dijon, France.
- ²⁰ Dijon University Hospital, GIMI institute, Dijon, France.
- ²¹ University of Burgundy-Franche Comté, Dijon Economics Laboratory, Dijon, France.
- ²² University of Burgundy-Franche Comté, FHU-TRANSLAD, Dijon, France.
- ²³ CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Baldiri Reixac 4, Barcelona 08028, Spain.
- ²⁴ Universitat Pompeu Fabra (UPF), Barcelona, Spain.
- ²⁵ EURORDIS-Rare Diseases Europe, Sant Antoni Maria Claret 167 - 08025 Barcelona, Spain.
- ²⁶ EURORDIS-Rare Diseases Europe, Plateforme Maladies Rares, 75014 Paris, France.
- ²⁷ INSERM, US14 - Orphanet, Plateforme Maladies Rares, 75014 Paris, France.
- ²⁸ Institut National de la Santé et de la Recherche Médicale (INSERM) U1127, Paris, France.
- ²⁹ Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UMR) 7225, Paris, France.
- ³⁰ Unité Mixte de Recherche en Santé 1127, Université Pierre et Marie Curie (Paris 06), Sorbonne Universités, Paris, France.
- ³¹ Institut du Cerveau -ICM, Paris, France.
- ³² Ecole Pratique des Hautes Etudes, Paris Sciences et Lettres Research University, Paris, France.
- ³³ Centre de Référence de Neurogénétique, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- ³⁴ Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- ³⁵ Sorbonne Université, INSERM UMRS_974, Center of Research in Myology, 75013 Paris, France.
- ³⁶ AP-HP, Centre de Référence de Pathologie Neuromusculaire Nord, Est, Ile-de-France, Institut de Myologie, G.H. Pitié-Salpêtrière, F-75013 Paris, France.
- ³⁷ Institut de Myologie, Equipe Bases de données, G.H. Pitié-Salpêtrière, F-75013 Paris, France.
- ³⁸ AP-HP, Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, G.H. Pitié-Salpêtrière, F-75013 Paris, France.
- ³⁹ Department of Biology and Medical Genetics, Charles University Prague-2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- ⁴⁰ European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.
- ⁴¹ Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
- ⁴² Florence Nightingale Faculty of Nursing and Midwifery, King's College, London, UK.
- ⁴³ Genetic Counselling, Genomics England, Queen Mary University of London, Dawson Hall, EC1M 6BQ, London.
- ⁴⁴ MRC Centre for Neuromuscular Diseases and National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, London, UK.
- ⁴⁵ Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
- ⁴⁶ Dubowitz Neuromuscular Centre, UCL Great Ormond Street Hospital, London, UK.
- ⁴⁷ NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom.
- ⁴⁸ Peripheral Neuropathy Research Group, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
- ⁴⁹ Institute Born Bunge, Antwerp, Belgium.
- ⁵⁰ Peripheral Neuropathy Research Group, University of Antwerp, Antwerp, Belgium.
- ⁵¹ Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium.
- ⁵² Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium.
- ⁵³ Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli," Napoli, Italy.
- ⁵⁴ Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
- ⁵⁵ Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Italy.
- ⁵⁶ Institute of Human Genetics, University of Bonn, Bonn, Germany.

-
- ⁵⁷ Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
- ⁵⁸ i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
- ⁵⁹ IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.
- ⁶⁰ Departament of Pathology, Faculty of Medicine, University of Porto, Portugal.
- ⁶¹ Departament of Genetics, Faculty of Medicine, University of Porto, Portugal.
- ⁶² CHUSJ, Centro Hospitalar e Universitário de São João, Porto, Portugal.
- ⁶³ Faculty of Sciences, University of Porto, Portugal.
- ⁶⁴ Department of Genetics, Genomics Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- ⁶⁵ NeuroCure Cluster of Excellence, Charité Universitätsklinikum, Charitéplatz 1, 10117 Berlin, Germany.
- ⁶⁶ College of Health, Well-being and Life-Sciences, Sheffield Hallam University, Sheffield, UK.
- ⁶⁷ Dept of Genetics, Assistance Publique-Hôpitaux de Paris - Université de Paris, Robert DEBRE University Hospital, 48 bd SERURIER, Paris, France.
- ⁶⁸ INSERM UMR 1141 "NeuroDiderot", Hôpital R DEBRE, Paris, France.
- ⁶⁹ Univ. Bordeaux, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale , F-33000 Bordeaux, France.
- ⁷⁰ Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, CHU Bordeaux – Hôpital Pellegrin, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France.
- ⁷¹ Institute of Rare Diseases Research, Spanish Undiagnosed Rare Diseases Cases Program (SpainUDP) & Undiagnosed Diseases Network International (UDNI), Instituto de Salud Carlos III, Madrid, Spain.
- ⁷² Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.
- ⁷³ Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy.
- ⁷⁴ Medical Genetics, University of Siena, Italy.
- ⁷⁵ Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy.
- ⁷⁶ Institute of Genomic Medicine and Rare Diseases, Semmelweis University, Budapest, Hungary.
- ⁷⁷ Clinical institute of genomic medicine, University medical centre Ljubljana, Slovenia.
- ⁷⁸ Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
- ⁷⁹ Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
- ⁸⁰ Neuromuscular Disorders Unit , Department of Pediatric Neurology. Hospital Sant Joan de Déu, Barcelona, Spain.
- ⁸¹ Department of Neuropediatrics and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- ⁸² Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
- ⁸³ Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.
- ⁸⁴ Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
- ⁸⁵ Folkhälsan Research Centre and Medicum, University of Helsinki, Helsinki, Finland.
- ⁸⁶ Tampere Neuromuscular Center, Tampere, Finland.
- ⁸⁷ Vasa Central Hospital, Vaasa, Finland.
- ⁸⁸ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
- ⁸⁹ Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- ⁹⁰ Medical Genetics Center (MGZ), Munich, Germany.
- ⁹¹ Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
- ⁹² Center for Personalized Oncology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.